MedTrace Logo

Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia

NCT01807364 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2016-06-17

No results posted yet for this study

Summary

Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal hyperplasia (CAH) from a fatal to a chronic lifelong disease. Long-term treatment, in particular the chronic (over-)treatment with glucocorticoids, may have an adverse effect on the cardiovascular risk profile in adult CAH patients. The objective of this study was to evaluate the cardiovascular risk profile of adult CAH patients.

Conditions

  • Congenital Adrenal Hyperplasia

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Anne Bachelot, MD, PhD · APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2015-09-30
Completion
2016-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01807364 on ClinicalTrials.gov